Concourse Financial Group Securities, Inc. Protalix Bio Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.52 Billion
- Q1 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.27MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.51 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$876,1750.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$874,1820.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$799,3560.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$523,1850.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...